Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy-Do Different Software Solutions Deliver Comparable Results?

Prostate-specific membrane antigen (PSMA) agreement biomarker comparability metabolic tumour volume (MTV) software total lesion PSMA

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
08 May 2020
Historique:
received: 12 03 2020
revised: 04 05 2020
accepted: 06 05 2020
entrez: 14 5 2020
pubmed: 14 5 2020
medline: 14 5 2020
Statut: epublish

Résumé

(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods:

Identifiants

pubmed: 32397223
pii: jcm9051390
doi: 10.3390/jcm9051390
pmc: PMC7290891
pii:
doi:

Types de publication

Journal Article

Langues

eng

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):602-612
pubmed: 29185010
J Nucl Med Technol. 2020 Mar;48(1):30-35
pubmed: 31604902
J Nucl Med. 2012 May;53(5):709-15
pubmed: 22492732
J Nucl Med. 2017 Dec;58(12):1962-1968
pubmed: 28522740
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126127
J Nucl Med. 2018 Jul;59(7):1070-1075
pubmed: 29242401
Ann Nucl Med. 2019 May;33(5):344-350
pubmed: 30746599
J Nucl Med. 2019 Sep;60(9):1277-1283
pubmed: 30850484
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1862-1872
pubmed: 29725716
PLoS One. 2015 Oct 16;10(10):e0140830
pubmed: 26473950
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Ann Nucl Med. 2019 Sep;33(9):681-688
pubmed: 31214958
Cancers (Basel). 2019 Dec 20;12(1):
pubmed: 31861942
J Nucl Med. 2020 Jan 10;:
pubmed: 31924729
J Nucl Med. 2012 Oct;53(10):1506-13
pubmed: 22895812
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Urol Ann. 2019 Apr-Jun;11(2):155-162
pubmed: 31040600
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Nucl Med Mol Imaging. 2018 Dec;52(6):420-429
pubmed: 30538773
Gynecol Oncol. 2011 Feb;120(2):270-4
pubmed: 21109300
J Nucl Med. 2014 Jun;55(6):898-904
pubmed: 24711649

Auteurs

Philipp E Hartrampf (PE)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

Marieke Heinrich (M)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

Anna Katharina Seitz (AK)

Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.

Joachim Brumberg (J)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

Ioannis Sokolakis (I)

Department of Urology, Martha-Maria Hospital Nuremberg, 90491 Nuremberg, Germany.

Charis Kalogirou (C)

Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.

Andreas Schirbel (A)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

Hubert Kübler (H)

Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.

Andreas K Buck (AK)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.

Constantin Lapa (C)

Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Nuclear Medicine, Medical Faculty, University of Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany.

Markus Krebs (M)

Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.

Classifications MeSH